Real-world data favour etelcalcetide for treating SHPT in multiethnic Asians
18 Dec 2023
byJairia Dela Cruz
Etelcalcetide proves beneficial in the real-world treatment of secondary hyperparathyroidism (SHPT) in multiethnic Asian haemodialysis patients, with the added advantage of reducing pill burden, as shown in a study from Singapore.
